At a glance
ClinicalIndex Comparison RecordN/ACompleted· 39,357 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Safety and Effectiveness of Warfarin, Dabigatran, and Rivaroxaban Among Japanese Patients With Non-valvular Atrial Fibrillation (NVAF) and Concomitant Coronary Artery Disease (CAD)
In Brief
An observational study for Coronary Artery Disease and Atrial Fibrillation. Completed, enrolled 39,357 participants across 1 site.
Detailed Summary
The study aims to evaluate the safety and effectiveness comparisons between warfarin, dabigatran, and rivaroxaban in routine clinical practice among Japanese non-valvular atrial fibrillation (NVAF) patients with concomitant coronary artery disease (CAD).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Atrial Fibrillation
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartMay 2022
Primary CompletionJul 2022
TodayJul 2026
First PostedSep 21, 2021
Enrollment StartMay 17, 2022
Primary CompletionJul 29, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.8 years ago